The Phase 3 trial called as EQUINOX will enroll a total of 800 patients at sites in the United States and abroad and include interim assessments at 20 percent and 50 percent of enrollment.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment